The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

"While the first wave of KRAS inhibitors have had limited impact in cancer care, this research shows that newer RAS ...

Colorectal cancer (CRC), a type of cancer that affects the large intestine and rectum, is one of the leading causes of cancer ...

Since the discovery of RAS gene mutations in DNA from human tumours around 40 years ago, KRAS has emerged as the most frequently mutated oncogene in human cancer, particularly in pancreatic ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.

Revolution Medicines is a clinical-stage pharma company with a market cap of ~6 billion. Click here to find out why RVMD ...

"These are the so-called RAS inhibitors." Research indicates that RAS inhibitors target a specific protein that signals the body to behave in a way that can halt cancer growth. "K-RAS is a gene ...

RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...

Roche/Chugai’s pan-RAS inhibitor LUNA18 has already completed a dose-ranging study, while Quanta’s multi-KRAS inhibitor QTX3034 is in preclinical development. Stephen Fawell, AZ’s head of ...